Clinical and Experimental Nephrology

, Volume 18, Issue 3, pp 424–431

Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury

  • Antonio Pisani
  • Massimo Sabbatini
  • Eleonora Riccio
  • Roberta Rossano
  • Michele Andreucci
  • Clemente Capasso
  • Viviana De Luca
  • Vincenzo Carginale
  • Mariano Bizzarri
  • Antonella Borrelli
  • Antonella Schiattarella
  • Michele Santangelo
  • Aldo Mancini
Original Article

Abstract

Background

Contrast media (CM)-induced nephropathy (CIN) is an acute deterioration of renal function following administration of CM mediated to a large extent by the increased production of ROS within the kidney. Aim of this study was to evaluate whether a novel isoform of a recombinant Manganese SOD (rMnSOD) could provide an effective protection against CIN; this molecule shares the same ability of physiological SODs in scavenging reactive oxygen species (ROS) but, due to its peculiar properties, enters inside the cells after its administration.

Methods

We studied the effects rMnSOD on oxidative damage in a rat model of CIN in uninephrectomized rats, that were randomly assigned to 3 experimental Groups: Group CON, control rats treated with the vehicle of CM, Group HCM, rats treated with CM and Group SOD, rats treated with CM and rMnSOD.

Results

In normal rats, pretreatment with rMnSOD, reduced renal superoxide anion production, induced by the activation of NAPDH oxidase, by 84 % (p < 0.001). In rats of Group HCM, ROS production was almost doubled compared to rat of Group CON (p < 0.01) but returned to normal values in rats of Group SOD, where a significant increase of SOD activity was detected (+16 % vs HCM, p < 0.05). Administration of CM determined a striking fall of GFR in rats of Group HCM (−70 %, p < 0.001 vs CON), greatly blunted in Group SOD (−28 % vs CON, p < 0.01); this was associated with a lower presence of both tubular necrosis and intratubular casts in SOD-treated rats (both p < 0.01 vs Group HCM).

Conclusions

Our data indicate that rMnSOD is able to reduce renal oxidative stress, thus preventing the reduction of GFR and the renal histologic damage that follows CM administration.

Keywords

Contrast-induced nephropathy Superoxide dismutase Oxygen radicals 

Abbreviations

b.w.

Body weight

CIN

Contrast media-induced nephropathy

CM

Contrast media

DCF

Dichlorofluorescein

DCFH-DA

2′,7′-Dichlorofluorescin diacetate

GFR

Glomerular filtration rate

IF

Intensity Fluorescence

i.p.

Intraperitoneal

i.v.

Intravenous

LSA

Liposarcoma cell line

rMnSOD

Recombinant manganese superoxide dismutase

ROS

Reactive oxygen species

SOD

Superoxide dismutase

WST

Water-soluble tetrazolium salt

References

  1. 1.
    Rudnick MR, Cohen RM, Goldfarb S. Contrast media associated nephrotoxicity. Curr Opin Nephrol Hypertens. 1996;5:127–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998;53:230–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interven Radiol. 2001;12:3–9.CrossRefGoogle Scholar
  4. 4.
    Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. 1999;34:685–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258:115–20.Google Scholar
  6. 6.
    Fishbane S. N-acetylcysteine in the prevention of contrast induced nephropathy. Clin J Am Soc Nephrol. 2008;3:281–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20:193–200.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Wan XS, Devalaraja MN, St Clair DK. Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol. 1994;13:1127–36.Google Scholar
  10. 10.
    Wispe JR, Clark JC, Burhans MS, Kropp KE, Korfhagen TR, Whitsett JA. Synthesis and processing of the precursor for human manganosuperoxide dismutase. Biochim Biophys Acta. 1989;994:30–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Scott MD, Meshnick SR, Eaton JW. Superoxide dismutase amplifies organismal sensitivity to ionizing radiation. J Biol Chem. 1989;264:2498–501.PubMedGoogle Scholar
  12. 12.
    Guyton KZ, Kensler TW. Oxidative mechanisms in carcinogenesis. Br Med Bull. 1993;49:523–44.PubMedGoogle Scholar
  13. 13.
    Borrelli A, Schiattarella A, Mancini R, et al. A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med. 2009;46:110–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Rahman NA, Mori K, Mizukami M, Suzuki T, Takahashi N, Ohyama C. Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. Transplant Proc. 2009;41:3603–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Maeva G, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, Bosch J, Garcia-Pagán JC. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rat. J Hepatol. 2013; 58j:240–246.Google Scholar
  16. 16.
    Mancini A, Borrelli A, Schiattarella A, et al. Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent. Int J Cancer. 2008;123:2684–269.Google Scholar
  17. 17.
    Mancini A, Borrelli A, Schiattarella A, et al. Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line. Int J Cancer. 2006;119:932–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Sabbatini M, Pisani A, Uccello F, et al. Arginase inhibition slows the progression of renal failure in rats with renal ablation. Am J Physiol Renal Physiol. 2003;284:F680–7.PubMedGoogle Scholar
  19. 19.
    Anarat A, Duman N, Noyan A, et al. The role of endothelin in radiocontrast nephropathy. Int Urol Nephrol. 1997;29:609–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Toprak O, Cirit M, Tanrisev M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant. 2008;23:853–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Borrelli A, Schiattarella A, Mancini R, et al. The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amounts of Cisplatin into tumor cells inducing a fast apoptosis in vitro. Int J Cancer. 2011;128:453–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lebel CP, Ali SF, McKee M, Bondy SC. Organometal-induced increases in oxygen reactive species: the potential of 2′,7′-dichlorofluorescin diacetate as an index of neurotoxic damage. Toxicol Appl Pharmacol. 1990;104(1):17–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172:1461–71.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003;64(1):128–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74(4):1156–64.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Sabbatini M, Sansone G, Uccello F, et al. Functional versus structural changes in the pathophysiology of acute ischemic renal failure in aging rats. Kidney Int. 1994;45(5):1355–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Pica A, Di Santi A, Basile F, et al. Anti-cancer, anti-necrotic and imaging tumor marker role of a novel form of Manganese Superoxide Dismutase and its leader peptide. Int J Biol Biomed Eng. 2010;4:53–60.Google Scholar
  28. 28.
    Deray G, Baumelou B, Martinez F, et al. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. Clin Nephrol. 1991;36:93–6.PubMedGoogle Scholar
  29. 29.
    Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211–7.PubMedGoogle Scholar
  30. 30.
    Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114:5–14.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2013

Authors and Affiliations

  • Antonio Pisani
    • 1
  • Massimo Sabbatini
    • 1
  • Eleonora Riccio
    • 1
  • Roberta Rossano
    • 1
  • Michele Andreucci
    • 2
  • Clemente Capasso
    • 3
  • Viviana De Luca
    • 3
  • Vincenzo Carginale
    • 3
  • Mariano Bizzarri
    • 4
  • Antonella Borrelli
    • 5
  • Antonella Schiattarella
    • 5
  • Michele Santangelo
    • 6
  • Aldo Mancini
    • 5
  1. 1.Department of NephrologyUniversity Federico II of NaplesNaplesItaly
  2. 2.Department of NephrologyMagna Graecia UniversityCatanzaroItaly
  3. 3.CNR. Institute of Protein Biochemistry (IBP)NaplesItaly
  4. 4.Italian Space Agency, La Sapienza UniversityRomeItaly
  5. 5.National Cancer Institute G. PascaleNaplesItaly
  6. 6.Department of SurgeryUniversity Federico II of NaplesNaplesItaly

Personalised recommendations